A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma by Srinivasan, Sujaya et al.
A Ten-microRNA Expression Signature Predicts Survival
in Glioblastoma
Sujaya Srinivasan, Irene Rosita Pia Patric, Kumaravel Somasundaram*
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India
Abstract
Glioblastoma (GBM) is the most common and aggressive primary brain tumor with very poor patient median survival. To
identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression
data of GBM patients (n=222) derived from The Cancer Genome Atlas (TCGA) dataset. We divided the patients randomly
into training and testing sets with equal number in each group. We identified 10 significant miRNAs using Cox regression
analysis on the training set and formulated a risk score based on the expression signature of these miRNAs that segregated
the patients into high and low risk groups with significantly different survival times (hazard ratio [HR]=2.4; 95% CI=1.4–3.8;
p,0.0001). Of these 10 miRNAs, 7 were found to be risky miRNAs and 3 were found to be protective. This signature was
independently validated in the testing set (HR=1.7; 95% CI=1.1–2.8; p=0.002). GBM patients with high risk scores had
overall poor survival compared to the patients with low risk scores. Overall survival among the entire patient set was 35.0%
at 2 years, 21.5% at 3 years, 18.5% at 4 years and 11.8% at 5 years in the low risk group, versus 11.0%, 5.5%, 0.0 and 0.0%
respectively in the high risk group (HR=2.0; 95% CI=1.4–2.8; p,0.0001). Cox multivariate analysis with patient age as a
covariate on the entire patient set identified risk score based on the 10 miRNA expression signature to be an independent
predictor of patient survival (HR=1.120; 95% CI=1.04–1.20; p=0.003). Thus we have identified a miRNA expression
signature that can predict GBM patient survival. These findings may have implications in the understanding of gliom-
agenesis, development of targeted therapy and selection of high risk cancer patients for adjuvant therapy.
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Introduction
The grade IV astrocytoma, GBM, is the most common and
malignant primary adult brain cancer [1]. Despite advances in
treatment modalities, the median survival is very poor. Since
postoperative radiotherapy alone did not provide great benefit to
GBM patients, several attempts have been made to find suitable
adjuvant chemotherapy. The present standard treatment appears to
be maximal safe resection of the tumor followed by irradiation and
temozolomide adjuvant chemotherapy [2]. However, it was found
that not all patients were benefited from the addition of
temozolomide. Further analysis revealed that methylation of MGMT
promoter to be the strongest predictor for outcome and benefit from
temozolomide chemotherapy [2]. In addition, recent molecular and
genetic profiling studies have identified several markers and unique
signatures as prognostic and predictive factors of GBM [3,4].
MicroRNAs (miRNAs) are endogenous non-coding small RNAs,
which negatively regulate gene expression either by binding to the
39 UTR leading to inhibition of translation or degradation of
specific mRNA. Since miRNAs can act as Oncogenes or tumor
suppressor genes,theyhave been linkedtoa variety ofcancers[5]. It
has been shown that classification of multiple cancers based on
miRNA expression signatures is more accurate than mRNA based
signatures [6]. There have been a few attempts to profile miRNA
expression either by microarray or RT-PCR in different grades of
glioma [7–11]. Rao et al., profiled the expression of 756 miRNAs
using 39 malignant astrocytoma and 7 normal brain samples and
identified a 23-miRNA expression signatures which can discrimi-
nate anaplastic astrocytoma from glioblastoma [11]. Other studies
investigated the target identification and functional characterization
of specific miRNAs [8,10,12–17]. Many studies identifying miRNA
expression signatures predicting patient survival have been done in
several cancers like lung cancer, lymphocytic leukemia; lung
adenocarcinoma, breast and pancreas cancers [18–23]. However,
a miRNA signature that can predict the clinical outcome in GBM
patients has not been found so far.
In this study, we have subjected the miRNA expression data
from a total of 222 GBM patients derived from The Cancer
Genome Atlas (TCGA) data set to Cox proportional regression
analysis to identify the miRNAs that can predict patient survival.
By using a sample-splitting approach, a 10 miRNA expression
signature that can predict survival both in training and testing sets
was identified. More importantly, using multivariate analysis along
with patient age, the 10 miRNA expression signature was found to
be an independent predictor of patient survival.
Results
Identification of a 10 miRNA expression signature from
training set
The 222 GBM samples were divided randomly into a training
set (n=111) or a testing set (n=111). Table 1 gives the age and
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miRNA expression data corresponding to 305 miRNAs derived
from the training set was subjected to Cox proportional hazard
regression analysis to identify miRNAs, whose expression profile
could be significantly correlated to patient survival. We identified a
set of 10 miRNAs that were significantly correlated with patient
survival (Table 2). These 10 miRNAs were then used to create a
signature by calculating a risk score for each patient. A risk score
formula was obtained for predicting the patient survival (see
[materials and methods] for detail). Using the risk score formula,
the 10 miRNA expression signature risk score was calculated for
all patients in the training set. The patients were then ranked in
the training set according to their risk score. Using the 60
th
percentile risk score as cutoff in the training set, the patients were
divided into high and low risk groups. Patients belonging to high
risk group had a shorter median survival than patients with low
risk score (12.6 months versus 19.3 months, HR=2.4; 95%
CI=1.4–3.8; p=0.0006) (Figure 1 A; Table 3). Survival was
greater in the low risk group than in the high risk group
throughout the follow-up. Overall survival in the training set was
41.8% at 2 years, 25.6% at 3 years, 23.6% at 4 years and 14.8% at
5 years in the low risk group, versus 9.0%, 3.0%, 0.0 and 0.0%
respectively in the high risk group (HR=2.4; 95% CI=1.4–3.8;
p=0.0006) (Table 3; Figure S1).
Validation of the 10 miRNA expression signature for
survival prediction in the testing set
To validate our finding, we calculated the risk score for the 111
patients from the testing set. Using the same cut-off value that was
used for training set, the patients from the testing set were classified
into low risk and high risk groups and subjected to survival
comparison. Similar to the results obtained in the training set,
patients in the high risk group had shorter median survival than
patients in the low risk group (12.1 months versus 18.0 months;
HR=1.7; 95% CI=1.1–2.8; p=0.0207) (Figure 1 B; Table 3).
As was seen in the training set, patient survival in the low risk group
was better than that in the high-risk group throughout the 5 year
follow-up time (Table 3). Risk score based classification of the
entire patient set also gave a similar result with the high risk group
having a shorter median survival than the low risk group (12.6
months versus 18.3 months, HR=2.0; 95% CI=1.4–2.8;
p,0.0001) (Table 3). The higher overall survival of the low risk
group throughout the study period in training, testing and entire
patient sets compared to the high risk group is shown (Figure S1).
Nature of 10 miRNA expression signature
Additional investigation of 10 miRNA set yielded several
interesting observations. The distribution of miRNA expression
Table 1. Clinical characteristics of GBM patients according to their low or high risk group in the training set, the testing set and the
entire patient set.
Characteristic Training set p-value* Testing set p-value* Entire patient set p-value*
Low risk
(N=69)
High risk
(N=42)
Low risk
(N=68)
High risk
(N=43)
Low risk
(N=137)
High risk
(N=85)
Age (Mean 6 SD) 51.566.6 54.461.9 0.5 54612.7 58.3610.2 0.1 52.8614.8 56.4611.2 0.1
Gender
Female (%) 26 (37.7) 13 (31) 0.5 27 (39.7) 12 (27.9) 0.2 53 (38.7) 25 (29.4) 0.2
Male (%) 43 (62.3) 29 (69) 41 (60.3) 31 (72.1) 84 (61.3) 60 (70.6)
*Two-tailed p-value obtained from Mann-Whitney test.
doi:10.1371/journal.pone.0017438.t001
Table 2. Ten miRNA signature that predicts survival in glioblastoma patients.
No miRNA Type
Hazard
Ratio Coefficient
Permutation
p-value Median log2 ratio
# GBM Vs Normal
Low risk High risk Regulation
$ p-value*
1 hsa-miR-20a Protective 0.68 20.39 0.0004 1.83 0.86 upregulated ,0.0001
2 hsa-miR-106a 0.66 20.41 0.0005 1.67 0.65 upregulated ,0.0001
3 hsa-miR-17-5p 0.68 20.39 0.0008 1.60 0.69 upregulated ,0.0001
4 hsa-miR-31 Risky 1.32 0.28 0.0001 21.83 20.82 downregulated 0.0022
5 hsa-miR-222 1.26 0.23 0.0004 22.15 20.70 downregulated 0.0002
6 hsa-miR-148a 1.21 0.19 0.0010 1.16 2.83 upregulated ,0.0001
7 hsa-miR-221 1.27 0.24 0.0014 21.93 20.53 downregulated 0.0003
8 hsa-miR-146b 1.25 0.22 0.0025 0.10 1.22 upregulated ,0.0001
9 hsa-miR-200b 1.21 0.19 0.0029 20.02 0.83 upregulated ,0.0001
10 hsa-miR-193a 1.34 0.29 0.0045 1.05 2.10 upregulated ,0.0001
#Median of the log 2 transformed ratios of GBM vs Normal.
$type of regulation (upregulated or downregulated) in GBM in comparison to Normal.
*Two-tailed p-value obtained from Mann-Whitney test.
doi:10.1371/journal.pone.0017438.t002
microRNA Signature and GBM Patient Survival
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17438values, patient risk scores and survival status of patients were
analyzed independently for both training and testing set (Figure 2
and 3). There were 3 miRNAs that were protective and 7
miRNAs that were risky based on correlation of their expression
and association with patient survival (Table 2). Tumors from
patients belonging to high risk group tend to express higher levels
of risky miRNAs, whereas tumors from patients with low risk
group tend to express higher levels of protective miRNAs
(Figures 2A). Similar results were obtained in the testing set as
well (Figure 3A). A comparison of risk score with patient survival
status and risk score distribution among GBM patients of the
training set and test set are shown (Figure 2 B, C and 3 B, C). It
is interesting to note that the three protective miRNAs are up
regulated in glioblastomas (GBMs) compared to normal samples
(Table 2). However among risky miRNAs, three were down
regulated and four were up regulated in GBMs (Table 2).
We further carefully analyzed the 10 miRNA set to determine
whether a subset of miRNAs can be used to predict GBM patient
survival. The four most significant miRNAs from the set of 10, all
with permutation p#0.0005 with (miR-20a, miR-106A, miR-31
and miR-222) were chosen and their expression signature derived
risk score was used to predict GBM patient survival. The results
showed that unlike the ten miRNA signature, the four miRNA did
not consistently correlate with patient survival in training and
testing set (data not shown).
Multivariate regression analysis shows that the 10 miRNA
expression signature is independent of age
In order to ascertain whether the 10 miRNA expression
signature based risk score is an independent predictor of GBM
patient’s survival, we carried out Cox multivariate analysis. As has
been shown before, patient age also predicted the GBM patients
survival in univariate analysis (p,0.0001; HR=1.027; B=0.027)
(Table 4). The effect of risk score and age on GBM patient
survival was further evaluated by multivariate Cox proportional
hazard model. We found that both risk score (p=0.003;
Figure 1. Kaplan-Meier survival estimates overall survival of glioblastoma patients according to the 10 miRNA expression
signature. A) 111 GBM patients in the training data set. B) 111 GBM patients in the testing data set.
doi:10.1371/journal.pone.0017438.g001
Table 3. Kaplan Meier overall survival analysis in the training set, the testing set and the entire patient set.
Patient set
Deaths/Patient
(%)
Hazard Ratio
(95% CI)
Median survival
(months, 95% CI) Survival (95% CI)
1 year (%) 2 years (%) 3 years (%) 4 years (%) 5 years (%)
Training set
Low risk
(n=69)
57/69 (82.6) 1 19.3 (12.7–25.9) 66.5 (54.9–78.1) 41.8 (29.5–54.1) 25.6 (14.5–6.7) 23.6 (12.6–34.6) 14.8 (5–24.6)
High risk
(n=42)
38/42 (90.5) 2.4 (1.4–3.8) 12.6 (10.1–15.1) 50.6 (35.1–6.1) 9.0 (0.0–18.4) 3.0 (0.0–8.7) 0.0 0.0
Test set
Low risk
(n=68)
55/68 (80.9) 1 18.0 (14.5–21.5) 64.8 (52.8–76.8) 28 (16.4–39.6) 17.3 (7.5–27.1) 13.5 (5.1–21.9) 6.2 (0–13.5)
High risk
(n=43)
36/43 (83.7) 1.7 (1.1–2.8) 12.1 (6.8–17.4) 49.8 (34.5–64.1) 13.3 (2.2–24.4) 8.9 (0.0–19.3) 0.0 0.0
Entire
patient set
Low risk
(n=137)
112/137 (81.8) 1 18.3 (15–21.6) 65.6 (57.4–72.8) 35.0 (26.4–3.2) 21.5 (14.1–28.9) 18.5 (11.2–25.8) 11.8 (5.5–18.1)
High risk (n=85)74/85 (87.1) 2.0 (1.4–2.8) 12.6 (10.3–14.9) 51.4 (40.6–62.2) 11.0 (3.5–18.5) 5.5 (0–11.2) 0.0 0.0
doi:10.1371/journal.pone.0017438.t003
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B=0.019) are independent predictors of GBM patient survival
(Table 4).
Discussion
In this study, we have identified a ten miRNA signature that is
associated with survival of GBM patients. We confirmed these
findings in a testing set. Patients with a high risk score had shorter
survival even after including patient age as a variable in a
multivariate Cox model. These results suggest that miRNAs play
an important role in molecular pathogenesis, progression and
prognosis of GBMs.
Predicting the benefit of various cancer therapies to patients is
very important and forms the foundation of personalized cancer
therapy. While the clinical features like age and Karnofsky
performance status are known prognostic markers among GBM
patients, MGMT gene promoter methylation status is of great
interest in recent times because it predicted response of GBM
patients receiving temozolomide chemotherapy in addition to
irradiation [2]. Several other molecular markers with prognostic
and predictive significance in GBMs have been identified [24].
Except for a few recent reports on the role of miRNAs in GBM
prognosis, the possibility of prognostic miRNA signatures have not
been investigated [25]. To our knowledge, this is the first report of
a miRNA expression signature predicting GBM patient survival.
The ten miRNA signature identified in this study included three
miRNAs (miR-20a, miR-106a and miR-17-5p) that were
protective and seven miRNAs (hsa-miR-31, hsa-miR-222, hsa-
miR-148a, hsa-miR-221, hsa-miR-146b, hsa-miR-200b and hsa-
miR-193a) that were risky with respect to their association
between their expression and patient survival. The protective
miRNAs were expressed at a higher level in the low risk group
compared to the high risk group and the risky miRNAs were
expressed at a higher level in the high risk group than in the low
risk group. The protective and risky nature of these miRNAs is
suggestive of their functions being either inhibitory or promoting,
respectively, of various properties of cancer cells like proliferation,
migration and invasion etc.
miR-31 has been shown to be an inhibitor of breast cancer
metastasis by targeting RhoA, RDX and ITGA which are
involved in tumor motility, invasion and resistance to anoikis
[26]. However, miR-31 has also been shown to be an oncogenic
miRNA in lung cancer by targeting tumor suppressor genes and in
head and neck cancer by targeting factor-inhibiting hypoxia-
inducible factor (FIH) [27,28]. Both miR-221 and 222 have shown
to be upregulated in multiple cancers including glioblastoma,
linked to promoting proliferation and radioresistance by targeting
PTEN, p27 and p57 [29–31]. Overexpression of miR-221 and
miR222 has been shown to be associated with poor survival in
hepatocellular carcinoma, pancreatic cancer and cervical cancer
[32–34]. Further, a low expression of p27Kip1, a target of miR-
221 and 222, has been correlated to poor prognosis in astrocytoms
[35–37]. miR-148a has been shown to regulate DNA methylation
by targeting DNA methylatransferase 1 (DNMT1) [38]. While
Chou et al. [39] reported higher expression of miR-146b in high
risk adult papillary thyroid carcinoma, other reports indicate miR-
146b is a metastatsis suppressor by targeting matrix metallopro-
teases [39–41]. Similar to our results, higher miR-146b levels is
correlated to poor prognosis in squamous cell lung cancer [42].
With respect to miR-200b, while Xia et al identified it to promote
S-phase entry by targeting RND3 and increasing cyclin D1
Figure 2. Ten miRNA Risk-Score Analysis of 111 GBM patients (training set). A) Heat map of ten miRNA expression profiles of GBM patients;
rows represent risky and protective miRNAs, and columns represent patients. The blue line represents the miRNA signature cutoff dividing patients
into low-risk and high-risk groups. B) Patient survival status along with risk score. C) miRNA risk-score distribution of the GBM patients.
doi:10.1371/journal.pone.0017438.g002
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epithelial-to mesenchymal transition with decreased cell migration
and increased sensitivity to EGFR-blocking agents [40,43]. In
malignant cutaneous melanoma, while increased expression of
miR-193a is associated with poor survival, miR-193a has been
identified as epigenetically silenced tumor suppressor miRNA in
oral cancer [44,45].
miR-106a, one of the protective miRNAs was found to be
overexpressed and oncogenic in human T-Cell leukemia [46].
However in good correlation with our data, low expression of
miR-106a was found to be associated with poor patient survival in
glioma and colon cancer [25,47]. The miR-17,92 cluster, which
contains two protective miRNAs, miR-17-5p and miR-20a, has
been found to accelerate the disease onset of Em-myc-induced B-
cell lymphoma, promote lung cancer growth in vitro, activated by c-
myc and promote tumor angiogenesis [48]. Interestingly, in breast
cancer, ovarian cancer and melanoma, miR-17,92 has been
shown to be deleted and found to inhibit cell proliferation upon
overexpression suggesting miR-17,92 cluster may have context
dependent functions [48]. Our results show that both miR-17-5p
and miR-20a are upregulated in GBMs with higher expression
correlating with increased survival. In good correlation with our
data, lower expression of E2F1, a target of miR-20a and cyclin D1,
a target of both miR-20a and miR-17 was found to predict longer
survival in gliomas [49–51].
Even though the median survival time remains in the 12–15
months range, the prognosis of individual patients is variable and
approximately 10% of the patients are known to survive for more
than 2 years [52]. At present, several molecular markers, including
MGMT promoter methylation status for GBM patient prognosis,
have been identified and many needs further validation before
their use in clinical settings [24]. The ten miRNA signature,
identified in this study, classifies patients successfully into low risk
and high risk groups in both training and testing sets. This may
help clinicians to identify patients belonging to high risk for more
effective adjuvant therapy in addition to the standard treatment
protocol. We also found that the ten miRNA signature is an
independent predictor of GBM patient survival.
Our finding that ten miRNA signature can predict GBM
patient’s survival also likely to generate potential molecular targets
for the development of anticancer therapy. Since miRNAs can
target multiple genes, more thorough studies are needed to
understand the mechanism of action of these miRNAs which is
likely to result in better understanding of glioma. In conclusion, we
Table 4. Cox regression analysis of risk score and age in the
entire patient set (n=222).
Variable Hazard ratio (95% CI) p-value*
Univariate analysis
Risk score 1.17 (1.09–1.25) ,0.0001
Age 1.03 (1.02–1.04) ,0.0001
Multivariate analysis
Risk score 1.12 (1.04–1.20) 0.003
Age 1.02 (1.01–1.03) 0.004
*Two-tailed p-value obtained from Mann-Whitney test.
doi:10.1371/journal.pone.0017438.t004
Figure 3. Ten miRNA Risk-Score Analysis of 111 GBM patients (test set). A) Heat map of ten miRNA expression profiles of GBM patients;
rows represent risky and protective miRNAs, and columns represent patients. The blue line represents the miRNA signature cutoff dividing patients
into low-risk and high-risk groups. B) Patient survival status along with risk score. C) miRNA risk-score distribution of the GBM patients.
doi:10.1371/journal.pone.0017438.g003
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survival with a lot of potential prognostic and therapeutic
implications for the GBM patient management.
Materials and Methods
TCGA miRNA dataset and patient information
miRNA expression data and the corresponding clinical data for
glioblastoma samples were downloaded from The Cancer Genome
Atlas (TCGA) data portal. The level 1 raw data for 364 samples,
which included 354 GBM and 10 normal samples, on the Agilent
Human 8x15K miRNA platform was downloaded from the TCGA
data portal in July 2010. The raw data was quantile normalized and
log2 transformed, and the probe-centric signals were converted to
gene-centric signals using the AgiMicroRNA package in R software
[53]. After filtering out genes that were not detected, there were a
total of 305 miRNAs for the 364 samples. We then calculated the
mean value for the normal samples for each miRNA, and
subtracted this value from all the samples for that miRNA, to come
up with a log2 ratio of GBM vs normal.
We obtained clinical information for those patients who had
survival information. We only selected those patients who had
undergone both radiotherapy and some form of chemotherapy. In
addition, we eliminated patients who had Karnofsky’s score lesser
than 70, and survival time lesser than 30 days, since these patients
might have died for reasons other than the disease itself. A total of
222 patients who fit these criteria were included for further analysis.
Statistical analysis
The 222 samples were randomly assigned to a training data set
(n=111) or a testing data set (n=111). The expression level of
each miRNA (n=306) was assessed by Cox regression analysis
using the BRB array tools [54] package in the training set.
Parametric test (p#0.01) identified a set of miRNAs significantly
correlated with survival. Using the permutation test method, with
10,000 permutations, we found 10 miRNAs were strongly
correlated with survival (p#0.005).
Using these 10 significant miRNAs, we constructed a formula
that would predict survival. This formula was devised using the
Cox regression coefficients derived from the Cox proportional
hazard analysis. Specifically, we assigned each patient a risk score
that is a linear combination of the expression levels of the
significant miRNAs weighted by their respective Cox regression
coefficients [55]. According to this model, patients having high risk
scores are expected to have poor survival outcomes as compared to
patients having low risk scores. The risk scores are calculated as
follows:
Risk score =(20.39 x expression of hsa-mir-20a) + (20.41 x
expression of hsa-mir-106a) + (20.39 x expression of hsa-mir-17-
5p) + (0.28 x expression of hsa-mir-31) + (0.23 x expression of hsa-
mir-222) + (0.19 x expression of hsa-mir-148a) + (0.24 x expression
of hsa-mir-221) + (0.22 x expression of hsa-mir-146b) + (0.19 x
expression of hsa-mir-200b) + (0.29 x expression of hsa-mir-193a).
The significant miRNAs that formed the signature were of two
types - risky and protective. Risky miRNAs were defined as those
that had hazard ratio for death greater than 1. Protective miRNAs
were defined as those that had hazard ratio for death less than 1.
Using this definition, we found 3 protective miRNAs and 7 risky
miRNAs.
We divided patients in the training data set into high-risk and
low-risk groups by risk score. We used the 60
th percentile risk score
as the cut-off, since this divided the training set patients into two
groups having different survival times with highest significance.
The Kaplan-Meier method was used to estimate overall survival
time for the two groups. Differences in survival times were
analyzed using the two-sided log rank test. We followed the
strategy of splitting patients into training and testing sets, as we
had no independent cohort that we could verify our signature
with. We used the splitting strategy as opposed to cross-validation,
since this has been found to be a better strategy [56]. We also used
Cox multivariate analysis to evaluate the contribution of patient
age as an independent prognostic factor. The miRNA risk score
and age were used in the multivariate analysis.
Supporting Information
Figure S1 study period in the training, the testing and the entire
patient sets.
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